The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: Single centre experience

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 2, 2012, Pages 101-107

  Hamidieh, Amir ^a   Kargar, Mona ^b   Jahani, Mohammad ^a   Alimoghaddam, Kamran ^a   Bahar, Babak ^a   Mousavi, Seyed Asadollah ^a   Iravani, Masoud ^a   Jalali, Arash ^a   Jalili, Mahdi ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

acute lymphoblastic leukemia; hematopoietic stem cell transplantation; pediatric

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMATINIB; METHOTREXATE; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD34 SELECTION; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; MONONUCLEAR CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 84857808053     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31824435a1     Document Type: Article

References (35)

1. Gaynon P, Harris R, Altman A, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG- 1941. J Clin Oncol. 2006;24:3150-3156.
2. Kolmannskog S, Flaegstad T, Helgestad J, et al. Childhood acute lymphoblastic leukemia in Norway 1992-2000. Tidsskr Nor Laegeforen. 2007;127:1493.
3. Friedmann A, Weinstein H. The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. Oncologist. 2000;5:321-328.
4. Gaynon P. Treatment of pediatric acute lymphoblastic leukemia: Progress achieved and challenges remaining. Curr Hematol Malig Rep. 2007;2:193-201.
5. Iori A, Arcese W, Milano F, et al. Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: A long-term follow-up. Haematologica. 2007; 92:1051-1058.
6. Rai S, Hudson M, McCammon E, et al. Implementing an intervention to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia: BONEII, a prospective placebo-controlled double-blind randomized interventional longitudinal study design. Contemp Clin Trials. 2008;29:711-719.
7. Uderzo C. Indications and role of allogeneic bone marrow transplantation in childhood very high risk acute lymphoblastic leukemia in first complete remission. Haematologica. 2000;85(11 suppl):9-11.
8. Mehta P, Davies S. Allogeneic transplantation for childhood ALL. Bone Marrow Transplant. 2007;41:133-139.
9. Zecca M, Pession A, Messina C, et al. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. J Clin Oncol. 1999;17:1838-1846.
10. Granados E, de La Camara R, Madero L, et al. Hematopoietic cell transplantation in acute lymphoblastic leukemia: Better long term event-free survival with conditioning regimens containing total body irradiation. Haematologica. 2000;85:1060-1067.
11. Bunin N, Aplenc R, Kamani N, et al. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant. 2003;32:543-548.
12. Ferry C, Socié G. Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned? Exp Hematol. 2003;31:1182-1186.
13. Davies S, Ramsay N, Klein J, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18:340-347.
14. Aschan J. Risk assessment in haematopoietic stem cell transplantation: Conditioning. Best Pract Res Clin Haematol. 2007;20:295-310.
15. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from Hl-A-matched sibling donors. Transplantation. 1974;18:295-304.
16. Shulman H, Sullivan K, Weiden P, et al. Chronic graft-versushost syndrome in man: A long-term clinicopathologic study of 20 seattle patients. Am J Med. 1980;69:204-217.
17. Pizzo Pa, Poplack Dg. Principles & Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams &Wilkins; 2010.
18. O'Brien M, Lacayo N. Acute leukemia in children. Dis Mon. 2008;54:202-225.
19. Uderzo C, Conter V, Dini G, et al. Treatment of childhood acute lymphoblastic leukemia after the first relapse: Curative strategies. Haematologica. 2001;86:1-7.
20. Borg M, Hughes T, Horvath N, et al. Renal toxicity after total body irradiation. Int J Radiat Oncol Biol Phys. 2002;54:1165-1173.
21. Jamieson C, Amylon M, Wong R, Blume K. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and highdose etoposide: A 15-year experience. Exp Hematol. 2003; 31:981-986.
22. Marks D, Forman S, Blume K, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006;12:438-453.
23. Bakker B, Massa G, van Rijn A, et al. Effects of total-body irradiation on growth, thyroid and pituitary gland in rhesus monkeys. Radiother Oncol. 1999;51:187-192.
24. Thomas O, Mahé M, Campion L, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys. 2001;49:125-131.
25. Jamil A, Bayoumy M, Termuhlen A, Wood J. Pediatric allogenic bone marrow transplantation: A comparison between related and unrelated grafts. Pediatr Int. 2002;17:184-188.
26. Cheng J, Schultheiss T, Wong J. Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys. 2008;71:1436-1443.
27. Miralbell R, Sancho G, Bieri S, et al. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: A prospective assessment. Int J Radiat Oncol Biol Phys. 2004;58:809-816.
28. Donato V, Iacari V, Zurlo A, et al. Fractionated total body irradiation in allogeneic bone marrow transplantation in leukemia patients: Analysis of prognostic factors and results in 136 patients. Radiother Oncol. 1998;48:267-276.
29. Belkacemi Y, Labopin M, Vernant J, et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: A study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys. 1998;41:659-668.
30. Perkins J, Kunin-Batson A, Youngren N, et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Med Pediatr Oncol. 2007;49:958-963.
31. Davies S, Rowe J, Appelbaum F. Indications for hematopoietic cell transplantation in acute leukemia. Biol Blood Marrow Transplant. 2008;14(1S):154-164.
32. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865-872.
33. Lee JH, Choi J, Kwon KA, et al. Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: Comparison with oral or intravenous busulfan with cyclophosphamide. Korean J Hematol. 2010;45:102-108.
34. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8: 493-500.
35. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood. 1992;79:2578-2582.